These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18006763)

  • 21. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer.
    Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Taniguchi T; Yokoi K; Osada H; Sekido Y
    J Surg Res; 2013 Jan; 179(1):24-32. PubMed ID: 22985775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
    Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
    Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.
    Suzuki C; Daigo Y; Ishikawa N; Kato T; Hayama S; Ito T; Tsuchiya E; Nakamura Y
    Cancer Res; 2005 Dec; 65(24):11314-25. PubMed ID: 16357138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
    J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer.
    Takahashi K; Furukawa C; Takano A; Ishikawa N; Kato T; Hayama S; Suzuki C; Yasui W; Inai K; Sone S; Ito T; Nishimura H; Tsuchiya E; Nakamura Y; Daigo Y
    Cancer Res; 2006 Oct; 66(19):9408-19. PubMed ID: 17018595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
    Ishikawa N; Takano A; Yasui W; Inai K; Nishimura H; Ito H; Miyagi Y; Nakayama H; Fujita M; Hosokawa M; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
    Cancer Res; 2007 Dec; 67(24):11601-11. PubMed ID: 18089789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
    Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
    Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
    Donnem T; Al-Saad S; Al-Shibli K; Delghandi MP; Persson M; Nilsen MN; Busund LT; Bremnes RM
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6649-57. PubMed ID: 18006765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ADAM8 as a novel serological and histochemical marker for lung cancer.
    Ishikawa N; Daigo Y; Yasui W; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
    Clin Cancer Res; 2004 Dec; 10(24):8363-70. PubMed ID: 15623614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas.
    Yamabuki T; Takano A; Hayama S; Ishikawa N; Kato T; Miyamoto M; Ito T; Ito H; Miyagi Y; Nakayama H; Fujita M; Hosokawa M; Tsuchiya E; Kohno N; Kondo S; Nakamura Y; Daigo Y
    Cancer Res; 2007 Mar; 67(6):2517-25. PubMed ID: 17363569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer.
    Xue D; Cheng P; Han M; Liu X; Xue L; Ye C; Wang K; Huang J
    Onco Targets Ther; 2018; 11():4755-4768. PubMed ID: 30127624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of immunohistochemical Rac1 expression in survival in early operable non-small cell lung cancer.
    Yuan K; Qian C; Zheng R
    Med Sci Monit; 2009 Nov; 15(11):BR313-9. PubMed ID: 19865048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer.
    Ohgino K; Soejima K; Yasuda H; Hayashi Y; Hamamoto J; Naoki K; Arai D; Ishioka K; Sato T; Terai H; Ikemura S; Yoda S; Tani T; Kuroda A; Betsuyaku T
    Lung Cancer; 2014 Jan; 83(1):90-6. PubMed ID: 24239165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer.
    Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Tanaka S; Yasui W; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
    Cancer Sci; 2006 Aug; 97(8):737-45. PubMed ID: 16863507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.
    Infante M; Allavena P; Garlanda C; Nebuloni M; Morenghi E; Rahal D; Roncalli M; Cavuto S; Pesce S; Monari M; Valaperta S; Montanelli A; Solomon D; Bottoni E; Errico V; Voulaz E; Bossi M; Chiesa G; Passera E; Mantovani A; Alloisio M
    Int J Cancer; 2016 Feb; 138(4):983-91. PubMed ID: 26348770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
    Hansen LV; Skov BG; Ploug M; Pappot H
    Lung Cancer; 2007 Nov; 58(2):260-6. PubMed ID: 17706320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.